Completed PHASE1 INTERVENTIONAL 4-arm NCT05769920

Dose Escalation TTHX1114 Ophthalmic Solution (EPI)

A Phase 1 Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of TTHX1114(NM141) Ophthalmic Solution In Healthy Adult Volunteers

Sponsor: Trefoil Therapeutics, Inc.

Conditions Corneal Epithelial Degeneration

Interventions TTHX1114(NM141) Ophthalmic Solution

Updated 4 times since 2023 Last updated: Apr 14, 2023 Started: Dec 6, 2022 Primary completion: Apr 12, 2023 Completion: Apr 12, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05769920, this PHASE1 trial focuses on Corneal Epithelial Degeneration and remains completed. Sponsored by Trefoil Therapeutics, Inc., it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Trefoil Therapeutics, Inc.

Data source: Trefoil Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cypress, United States